Edding Genor Group Holdings Limited (stock code: 6998) reported that its innovative small nucleic acid drug EDP167 has achieved first subject dosing in a Phase II clinical trial designed for adult patients with Homozygous Familial Hypercholesterolemia (HoFH).

According to the announcement dated 9 February 2026, this multicenter, dose-finding, open-label trial aims to assess the efficacy and safety of EDP167, with change in low-density lipoprotein cholesterol (LDL-C) levels relative to baseline after 24 weeks of first dosing as its primary endpoint. Assessment of this endpoint is expected to conclude in the fourth quarter of 2026.

EDP167 is presented as an siRNA therapeutic targeting hepatic angiotensin-like protein 3 (ANGPTL3), a key regulator involved in inhibiting lipoprotein lipase and endothelial lipase. The drug is intended for patients with dyslipidemia, particularly those with HoFH or mixed dyslipidemia, and functions independently of the LDL receptor pathway, overcoming limitations of conventional lipid-lowering therapies.

Prior to the start of the current Phase II trial, a randomized, double-blind, placebo-controlled, single ascending dose Phase I study was completed. Results from the Phase I study indicated a favorable safety and tolerability profile for EDP167, with related data scheduled for disclosure at an upcoming medical conference in 2026.

Edding Genor Group Holdings Limited focuses on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. The company has established a portfolio of originator-branded and innovative drugs through acquisitions and licensing agreements. It also operates production facilities transferred from multinational pharmaceutical companies, reflecting its production and quality management capabilities.